Pemoline in the Treatment of Stimulant Dependence - 5

This study has been withdrawn prior to recruitment.

( Study was never funded. )

First Received: September 20, 1999 Last Updated: August 25, 2008 History of Changes

Sponsor:	National Institute on Drug Abuse (NIDA)
Information provided by:	National Institute on Drug Abuse (NIDA)
ClinicalTrials.gov Identifier:	NCT00000340

Purpose

The purpose of this study is to assess the efficacy of pemoline in treating cocaine and/or methamphetamine dependent adults with comorbid Adult Attention Deficit Hyperactivity Disorder (ADHD).

Condition	Intervention	Phase
Cocaine-Related Disorders	Drug: Pemoline	Phase II

Study Type:	Interventional
Study Design:	Treatment
Official Title:	Pemoline in the Treatment of Stimulant Dependence

Resource links provided by NLM:

Drug Information available for: Pemoline

U.S. FDA Resources

Further study details as provided by National Institute on Drug Abuse (NIDA):

Primary Outcome Measures:

Retention
Depression
Incidence of stimulant use
Severity of stimulant withdrawal symptoms
ADHD symptom severity
Degree of drug craving
Frequency of IV drug use and sexual risk behaviors

Estimated Enrollment:	1
Study Start Date:	June 1996

Eligibility

Ages Eligible for Study:	21 Years to 50 Years
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

M/F ages 21-50. Meet DSM-IV criteria for cocaine dependence. Agree to conditions of the study and sign informed consent.

Exclusion Criteria:

Psychiatric disorder that requires medication therapy. History of seizures. Pregnant and/or nuring women. Dependence on ETOH or benzodiazepines or other sedative/hypnotics. Acute hepatitis. Other medical condtions that deem participation to be unsafe.

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00000340

Sponsors and Collaborators

National Institute on Drug Abuse (NIDA)

Investigators

Principal Investigator:

Walter Ling, M.D.

Friends Research Institute, Inc.

More Information

No publications provided

Study ID Numbers:	NIDA-3-0010-5, Y01-3-0010-5
Study First Received:	September 20, 1999
Last Updated:	August 25, 2008
ClinicalTrials.gov Identifier:	NCT00000340 History of Changes
Health Authority:	United States: Federal Government

Additional relevant MeSH terms:

Cocaine-Related Disorders
Pemoline
Mental Disorders
Therapeutic Uses
Physiological Effects of Drugs

Substance-Related Disorders
Disorders of Environmental Origin
Central Nervous System Stimulants
Central Nervous System Agents
Pharmacologic Actions

ClinicalTrials.gov processed this record on November 25, 2009